Latest Breaking News On - மருத்துவ முன்னேற்றம் - Page 5 : comparemela.com

DGAP-News: Immunic, Inc Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

DGAP-News: Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial Table: IMU-838 Shows Acceleration of Time to Clinical Improvement High-risk patients and patients aged over 65 years experienced a more substantial treatment benefit from IMU-838 than in the general patient population: - The 75% probability [5] to reach clinical improvement (based on investigator assessment) was accelerated by 3.8 days in IMU-838 treated high-risk patients [6], as compared to placebo (FAS). - The 75% probability [5] to reach clinical improvement (based on investigator assessment) was accelerated by 4.8 days in IMU-838 treated elderly patients (65 years or older), as compared to placebo (FAS).

United statesPaula schwartzEdna kaplanJessica breuAndreas muehlerDaniel vittExchange commissionWorld health organizationRx communications groupImmunic incDistribution servicesAnnounces that oral treatmentClinical activityMultiple secondary endpointsIncluding clinically meaningful improvementsClinical recovery

Synairgen plc: Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients

Synairgen plc: Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients ( Synairgen or the Company ) Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients Southampton, UK - 15 February 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that dosing has begun in the inhaled interferon beta formulation (SNG001) sub-study of the ACTIV-2 Phase II/III trial, evaluating patients with mild to moderate COVID-19 symptoms not yet requiring hospitalisation. Richard Marsden, CEO of Synairgen, said:

United kingdomOlivia manserGeoff nashRichard marsdenJohn wardDonna daviesJames thompsonDuncan monteithJames blackMary jane elliottRatko djukanovicFreddie barnfieldNumis securities limited joint brokerUniversity of southampton professors sir stephen holgateNational institute of allergyNational institutes of health

Nebulised interferon beta-1a for patients with COVID-19

Nebulised interferon beta-1a for patients with COVID-19
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

Care study groupElsevier ltdThe lancet respiratory medicinePhillip monkClinical improvementAcute care studyClin investView largeபராமரிப்பு படிப்பு குழுபிலிப் துறவிமருத்துவ முன்னேற்றம்எடுப்போசை பராமரிப்பு படிப்புகிளினிக் முதலீடுபார்வை பெரியது

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

United kingdomSynairgen researchClinical improvementஒன்றுபட்டது கிஂக்டம்மருத்துவ முன்னேற்றம்

Investegate |Synairgen plc Announcements | Synairgen plc: Inclusion in US ACTIV-2 trial

About Synairgen Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic. Synairgen is currently fully focused on progressing its inhaled interferon beta1a broad spectrum antiviral drug as an effective treatment for people suffering with COVID-19 infection. Synairgen s differentiating human biology BioBank platform and world-renowned international academic KOL network has broader applicability for lung viral defence in other respiratory disorders including asthma and COPD. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com COVID-19 COVID-19, caused by the SARS-CoV-2 virus, is a global threat and there is an urgent need to assess new treatments to prevent and effectively treat the severe lower respiratory tract illness that can occur with this disease. Older people

United kingdomOlivia manserGeoff nashRichard marsdenJohn wardDonna daviesJames thompsonDuncan monteithJames blackMary jane elliottRatko djukanovicFreddie barnfieldNumis securities limited joint brokerUs national institute of allergyHuman servicesClinical trials group